Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment

Journal of Cardiovascular Medicine

Volumn 13, Issue 7, 2012, Pages 415-422

  Vaduganathan, Muthiah ^a   Gheorghiade, Mihai ^b   Pang, Peter S ^b   Konstam, Marvin A ^c   Zannad, Faiez ^d   Swedberg, Karl ^e   Grinfeld, Liliana ^f   Burnett, John C ^g   Krasa, Holly B ^h   Zimmer, Christopher ^h   Blair, John ^b   Ouyang, John ^h   Maggioni, Aldo P ⁱ  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITÉ DE LORRAINE   (France)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^g MAYO CLINIC   (United States)

^h OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

ⁱ ANMCO RESEARCH CENTER   (Italy)

Author keywords

acute heart failure; hemodynamics; hypotension; renal failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; MINERALOCORTICOID ANTAGONIST; SODIUM; TOLVAPTAN;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART PALPITATION; HIGH RISK POPULATION; HUMAN; HYPERNATREMIA; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OLIGURIA; OUTCOME ASSESSMENT; PRURITUS; RETROSPECTIVE STUDY; SIDE EFFECT; SODIUM BLOOD LEVEL; SYMPTOM; SYSTOLIC BLOOD PRESSURE; THIRST; TREATMENT OUTCOME; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BENZAZEPINES; CARDIOVASCULAR AGENTS; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; RENAL INSUFFICIENCY; SODIUM; TREATMENT OUTCOME;

EID: 84862569857     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328355a740     Document Type: Article

References (34)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics: 2009 update -A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119:480-486.
2. Nieminen MS, Harjola VP. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005; 96:5G-10G. (Pubitemid 41338069)
3. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the medicare fee-for-service program. N Engl J Med 2009; 360:1418-1428.
4. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296:2217-2226. (Pubitemid 44708052)
5. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50:768-777. (Pubitemid 47243795)
6. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293:572-580. (Pubitemid 40171239)
7. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007; 153:98-104. (Pubitemid 44880871)
8. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure -A meta-regression analysis. Eur J Heart Fail 2002; 4:515-529. (Pubitemid 36564973)
9. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003; 290:2581-2587. (Pubitemid 37443288)
10. Filippatos G, Rossi J, Lloyd-Jones DM, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail 2007; 13:360-364. (Pubitemid 46977793)
11. Akhter MW, Aronson D, Bitar F, et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 2004; 94:957-960. (Pubitemid 39349569)
12. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35:681-689. (Pubitemid 30167025)
13. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002; 8:136-141. (Pubitemid 34857278)
14. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 2004; 116:466-473. (Pubitemid 38388616)
15. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004; 10:460-466.
16. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102:203-210. (Pubitemid 30451778)
17. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113:671-678.
18. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47:1987-1996.
19. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients or 65 years of age with heart failure. Am J Cardiol 2000; 85:1110-1113. (Pubitemid 30214258)
20. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43:61-67. (Pubitemid 38045917)
21. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (posh). Eur Heart J 2006; 27:1216-1222.
22. Tavazzi L, Maggioni AP, Lucci D, et al. Nationwide survey on acute heart failure in cardiology ward services in italy. Eur Heart J 2006; 27:1207-1215.
23. Cleland JG, Coletta A, Witte K. Practical applications of intravenous diuretic therapy in decompensated heart failure. Am J Med 2006; 119:S26-S36. (Pubitemid 44738817)
24. Hill JA, Yancy CW, Abraham WT. Beyond diuretics: management of volume overload in acute heart failure syndromes. Am J Med 2006; 119:S37-S44. (Pubitemid 44738818)
25. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007; 9:1064-1069. (Pubitemid 47451811)
26. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46:1785-1791. (Pubitemid 41579797)
27. Gheorghiade M, Gattis WA, OConnor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291:1963-1971. (Pubitemid 38544277)
28. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a doubleblind, randomized trial. Circulation 2003; 107:2690-2696. (Pubitemid 36667242)
29. Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST). J Card Fail 2005; 11:260-269. (Pubitemid 40626781)
30. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA 2007; 297:1332-1343. (Pubitemid 46513234)
31. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007; 297:1319-1331. (Pubitemid 46513233)
32. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology. Eur Heart J 2005; 26:384-416. (Pubitemid 40283098)
33. Kovesdy CP, Lott EH, Lu JL, et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 2012; 125:677-684.
34. Xhyheri B, Bugiardini R. Diagnosis and treatment of heart disease: are women different from men? Prog Cardiovasc Dis 2010; 53:227-236.